bannercategory Archives | Future Medicine India

bannercategory

Belantamab gets approval as a fourth-line therapy for multiple myeloma

Belantamab mafodotin (Blenrep) has been recently approved by the US FDA as a fourth-line therapy in treating adult patients with relapsed or refractory multiple myeloma, announced GlaxoSmithKline.

FM
Read More..